Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Asthma
Efficacy
Exacerbations
Long-acting muscarinic antagonist
Lung function
Persistent airflow limitation
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
15
12
2022
revised:
20
02
2023
accepted:
23
02
2023
medline:
25
4
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ Patients with post-bronchodilator FEV Of the 3092 randomised patients, 64% (n = 1981) met the criteria for PAL. Overall, there was no evidence of treatment difference between PAL and non-PAL subgroups (interaction P-value for FEV Once-daily fixed-dose MF/IND/GLY was efficacious in asthma patients with and without persistent airflow limitation.
Sections du résumé
BACKGROUND
A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ
METHODS
Patients with post-bronchodilator FEV
RESULTS
Of the 3092 randomised patients, 64% (n = 1981) met the criteria for PAL. Overall, there was no evidence of treatment difference between PAL and non-PAL subgroups (interaction P-value for FEV
CONCLUSIONS
Once-daily fixed-dose MF/IND/GLY was efficacious in asthma patients with and without persistent airflow limitation.
Identifiants
pubmed: 36906187
pii: S0954-6111(23)00060-4
doi: 10.1016/j.rmed.2023.107172
pii:
doi:
Substances chimiques
Glycopyrrolate
V92SO9WP2I
Mometasone Furoate
04201GDN4R
indacaterol
8OR09251MQ
Iridium
44448S9773
Drug Combinations
0
Indans
0
Bronchodilator Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107172Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest RVZS reports personal fees from Aspen/GSK, Pfizer, Roche, MSD, AstraZeneca, Novartis, Glenmark, Boehringer Ingelheim and Cipla, outside the submitted work. HAK reports grants and consultancy/advisory board participation from/for Novartis during the conduct of the study, grants and consultancy/advisory board participation from/for GlaxoSmithKline and Boehringer Ingelheim, and a grant from Chiesi, outside the submitted work. All were paid to his institution. JFM reports personal fees and grants from Novartis during the conduct of the study, personal fees from AstraZeneca, grants and personal fees from Sanofi and personal fees from ImmunoTek. KK reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Novartis and Menarini; personal fees from Sanofi; and grants from NuvoAir, outside the submitted work, and was an employee of Novartis Pharma AG until October 31, 2018. KRC reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Sanofi, Regeneron, Novartis and Takeda; personal fees from CSL Behring, Inhibrx and Kamada; and grants from Vertex, outside the submitted work. MH, AMT, KM, DB and DL are employees of Novartis Pharma AG. PD is an employee of Novartis Pharmaceutical Corporation.